Format

Send to

Choose Destination
Cancer Lett. 2014 Dec 28;355(2):232-41. doi: 10.1016/j.canlet.2014.08.037. Epub 2014 Sep 19.

Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways.

Author information

1
Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA; Guang An Men Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
2
Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA.
3
Neuronal Networks Section, Intramural Research Program, National Institute on Drug Abuse, NIH, 251 Bayview Blvd, Baltimore, MD 21224, USA.
4
Leidos Biomedical, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
5
Guang An Men Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
6
Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA. Electronic address: howardz@mail.nih.gov.

Abstract

Cancer pain is a deleterious consequence of tumor growth and related inflammation. Opioids and anti-inflammatory drugs provide first line treatment for cancer pain, but both are limited by side effects. Fufang Kushen injection (FKI) is GMP produced, traditional Chinese medicine used alone or with chemotherapy to reduce cancer-associated pain. FKI limited mouse sarcoma growth both in vivo and in vitro, in part, by reducing the phosphorylation of ERK and AKT kinases and BAD. FKI inhibited TRPV1 mediated capsaicin-induced ERK phosphorylation and reduced tumor-induced proinflammatory cytokine production. Thus, FKI limited cancer pain both directly by blocking TRPV1 signaling and indirectly by reducing tumor growth.

KEYWORDS:

ERK; Fufang Kushen injection; Hyperalgesia; Sarcoma; TRPV1

PMID:
25242356
PMCID:
PMC4253542
DOI:
10.1016/j.canlet.2014.08.037
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center